Market Newsdesk

December 10, 2020 10:50 pm

AbCellera Announces Pricing of Initial Public Offering

AbCellera Announces Pricing of Initial Public Offering

VANCOUVER, British Columbia–(BUSINESS WIRE)–
AbCellera Biologics Inc. (“AbCellera”), a technology company that aims to become the centralized operating system for next-generation antibody discovery, today announced the pricing of its initial public offering of 24,150,000 common shares at a price to the public of $20.00 per share. All of the common shares are being offered by AbCellera. In addition, AbCellera has granted the underwriters a 30-day option to purchase up to 3,622,500 additional common shares at the initial public offering price, less underwriting discounts and commissions. The shares are expected to begin trading on The Nasdaq Global Select Market on December 11, 2020 under the ticker symbol “ABCL.” The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be $483.0 million, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on December 15, 2020, subject to satisfaction of customary closing conditions.

Credit Suisse, Stifel, Berenberg, SVB Leerink and BMO Capital Markets are acting as joint book-running managers for the offering.

As previously announced in November 2020, in connection with its acquisition of Trianni, Inc., AbCellera issued convertible promissory notes to certain investors in an aggregate amount of approximately $90.0 million (the “Notes”). Upon the closing of the offering, the Notes will convert into common shares at a price of $17.00 per share, which is 85% of the initial public offering price.

A registration statement on Form S-1 relating to the common shares sold in the initial public offering has been filed with the Securities and Exchange Commission and became effective on December 10, 2020. The offering is made only by means of a prospectus, copies of which may be obtained, when available, from: Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, 6933 Louis Stephens Drive, Morrisville, NC 27560, by telephone at (800) 221-1037, or by email at [email protected]; Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720, or by email at [email protected]; Berenberg Capital Markets LLC, Attention: Investment Banking, 1251 Avenue of the Americas, 53rd Floor, New York, NY 10020, or by telephone at (646) 949-9000, or by email at [email protected]; SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at (800) 808-7525, ext. 6132, or by email at [email protected]; or BMO Capital Markets Corp. at 3 Times Square, 25th Floor, New York, NY 10036, Attention: Equity Syndicate Department, by telephone at (800) 414-3627, or by email to [email protected].

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. AbCellera is conducting its initial public offering in the United States and not in any Canadian jurisdiction.

About AbCellera Biologics

AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce cost, and tackle the toughest problems in drug development.

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will,” and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, statements regarding completion, timing and anticipated size of the initial public offering and the expected commencement of trading on the Nasdaq Global Select Market.

Any forward-looking statements in this press release are based on AbCellera’s current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, completion of the proposed public offering on the anticipated terms, or at all, market conditions and the satisfaction of customary closing conditions related to the initial public offering. These and other risks concerning AbCellera’s programs and operations are described in additional detail in its registration statement on Form S-1, which is on file with the SEC. AbCellera explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201210006243/en/

Jessica Yingling, Ph.D.

+1 (236) 521-6774

[email protected]

KEYWORDS: North America Canada

INDUSTRY KEYWORDS: Technology Biotechnology Health Other Technology

MEDIA:

Logo

December 10, 2020 10:39 pm

4D Molecular Therapeutics Announces Upsized Pricing of Initial Public Offering

EMERYVILLE, Calif., Dec. 10, 2020 (GLOBE NEWSWIRE) — 4D Molecular Therapeutics, Inc. (4DMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced today the pricing of its initial public offering of 8,400,000 shares of its common stock at a public offering price of $23.00 per share. All of the shares are being offered by 4DMT. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by 4DMT, are expected to be $193.2 million. In connection with the offering, 4DMT has granted the underwriters a 30-day option to purchase up to 1,260,000 additional shares of common stock. The shares are expected to begin trading on the Nasdaq Global Select Market on December 11, 2020 under the ticker symbol “FDMT.” The offering is expected to close on December 15, 2020, subject to satisfaction of customary closing conditions.

Goldman Sachs & Co. LLC, BofA Securities and Evercore ISI are acting as book-running managers for the offering.

The offering will be made only by means of a prospectus. A copy of the final prospectus relating to this offering, when available, may be obtained from: Goldman Sachs & Co. LLC, Prospectus Department, 200 West Street, New York, New York 10282, by telephone at (866) 471-2526, or by email at [email protected]; BofA Securities, Attention: Prospectus Department, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, North Carolina 28255-001, or by email at [email protected]; or Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 36th Floor, New York, New York 10055, by telephone at (888) 474-0200, or by email: [email protected].

Registration statements relating to these securities became effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Contacts:

Media:

Theresa Janke
[email protected]

Investors:

Mike Zanoni
Endurance Advisors
[email protected]

December 10, 2020 10:16 pm

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Boral Limited – BOALY

PR Newswire

NEW YORK, Dec. 10, 2020 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Boral Limited (“Boral” or the “Company”) (OTCMKTS: BOALY). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.

The investigation concerns whether Boral and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]

On December 5, 2019, Boral disclosed that it had identified financial irregularities in its North American window business, involving the misreporting of inventory levels and raw material and labor cost at the window plants, and was conducting an internal investigation into the matter. Then, on February 9, 2020, Boral revealed that its investigation had found inflated earnings at its North American window-making business and announced that the Company had fired the division’s vice president of finance and financial controller.

On this news, Boral’s American depositary receipt price fell $1.08 per share, or 7.83%, to close at $12.72 per share on February 10, 2020.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

CONTACT:

Robert S. Willoughby

Pomerantz LLP
[email protected]
888-476-6529 ext. 7980

View original content:http://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-boral-limited—boaly-301190952.html

SOURCE Pomerantz LLP

December 10, 2020 10:05 pm

Robert F. Kennedy Human Rights Celebrates Five Courageous Humanitarians at its Star-Studded 2020 Ripple of Hope Award Ceremony

The organization also announced it will be broadcasting this year’s Ripple of Hope Award ceremony in a special Facebook Premiere on December 17, making the illustrious celebration open and available to the public for the first time.

New York, NY, Dec. 10, 2020 (GLOBE NEWSWIRE) — On Thursday, Robert F. Kennedy Human Rights hosted its 52nd annual Ripple of Hope Award ceremony, recognizing five courageous humanitarians for their pursuit of racial and economic equality, social justice, and civil rights: Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases; Dolores Huerta, founder and president of the Dolores Huerta Foundation and co-founder of United Farm Workers of America; Colin Kaepernick, human rights activist, co-founder of Know Your Rights Camp, and Super Bowl quarterback; Dan Schulman, president and chief executive officer of PayPal; and Dan Springer, chief executive officer of DocuSign.

Thanks to the generous support of the evening’s attendees, Robert F. Kennedy Human Rights has announced it will debut an encore presentation of the Ripple of Hope Award ceremony on Thursday, December 17, at 7:00 p.m. ET, making the program free and available to the public in its entirety for the first time. You can RSVP for the Facebook Premiere here.

As we near the end of this exceptionally difficult year, one that has seen the courageous pursuit of equality and justice become political and even adversarial, the Ripple of Hope Award laureates urged the audience to continue speaking their truth to power and demanding social change.

“We live in a culturally charged world, where even listening to an opposing point of view can be seen as treasonous,” said Dan Schulman, president and chief executive officer of PayPal, in his remarks. “But this is the time we live in and I feel deeply that I have an obligation to create a more just world. Our democracy relies on each of us rising above our own self-interest to create a better system for everyone.”

“My father said ‘although we may live in challenging times, so are they filled with opportunity.’ Our laureates’ actions send encouraging messages of hope and possibility,” said Kerry Kennedy, president of Robert F. Kennedy Human Rights. “Their commitment to equality, capacity for innovative solutions, respect for human rights, and vision for a better future inspire us all.”

Typically an in-person event, this year’s virtual celebration provided unprecedented access to the Ripple of Hope laureates—several of whom have faced undue criticism, harassment, and even death threats in their high-profile work defending human rights—and gathered influential leaders across government, business, advocacy, and entertainment. Among those in attendance: Katie Couric, Chris Tucker, Martin Sheen, Alfre Woodard, Dan Rather, Keegan-Michael Key, Gloria Steinem, Cornel West, Jake Tapper, Joy Behar, Rep. Cedric Richmond, George Lopez, Don Lemon, Carlos Santana, Sam Waterston, Aloe Blacc, and Martin Luther King III.

For more on the 2020 Ripple of Hope Award ceremony and this year’s laureates—including exclusive photos, videos, and transcripts of the laureates’ remarks—visit RFKGala.com.

Robert F. Kennedy Human Rights

We are a non-partisan, not-for-profit organization that has worked to realize Robert F. Kennedy’s dream of a more just and peaceful world since 1968. In partnership with local activists, we advocate for key human rights issues—championing changemakers and pursuing strategic litigation at home and around the world. And to ensure change that lasts, we foster a social-good approach to business and investment and educate millions of students about human rights and social justice.

Attachments

Minhee Cho
Robert F. Kennedy Human Rights
[email protected]

December 10, 2020 9:54 pm

Motive Capital Corp Announces Pricing of Upsized $360 Million Initial Public Offering

Motive Capital Corp Announces Pricing of Upsized $360 Million Initial Public Offering

NEW YORK–(BUSINESS WIRE)–
Motive Capital Corp (the “Company”) today announced the pricing of its initial public offering of 36,000,000 units at a price of $10.00 per unit. The Company has granted the underwriters of the offering a 45-day option to purchase up to an additional 5,400,000 units at the public offering price. The units will be listed on the New York Stock Exchange (the “NYSE”) and trade under the ticker symbol “MOTV.U” beginning December 11, 2020. Each unit consists of one share of the Company’s Class A common stock and one-third of one warrant. Each whole warrant entitles the holder to one share of the Company’s Class A common stock at a price of $11.50 per share. Once the securities comprising the units begin separate trading, the Class A common stock and warrants are expected to be listed on the NYSE under the symbols “MOTV” and “MOTV WS”, respectively.

Motive Capital Funds Sponsor, LLC, an affiliate of Motive Partners, is the sponsor of the Company. UBS Investment Bank and J.P. Morgan are acting as joint book-running managers for the offering.

The offering is being made only by means of a prospectus. When available, copies of the prospectus may be obtained, for free by visiting EDGAR on the SEC’s website at www.sec.gov. Alternatively, copies of the preliminary prospectus, when available, may be obtained for free from the offices of UBS Securities LLC, Attention: Prospectus Department, 1285 Avenue of the Americas, New York, New York 10019, telephone: (888) 827-7275 or email: [email protected]; or J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, telephone: 1-866-803-9204, or by email at [email protected].

A registration statement relating to the securities became effective on December 10, 2020. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Motive Capital Corp

Motive Capital Corp is a newly incorporated blank check company whose business purpose is to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses or entities.

Cautionary Statement Concerning Forward-Looking Statements

Certain statements contained in this press release constitute forward-looking statements. All of these statements are based on management’s expectations as well as estimates and assumptions prepared by management that, although they believe to be reasonable, are inherently uncertain. These statements involve risks and uncertainties, including, but not limited to, economic, competitive, governmental and technological factors outside of Company’s control that may cause its business, industry, strategy, financing activities or actual results to differ materially. The Company undertakes no obligation to update or revise any of the forward-looking statements contained herein, whether as a result of new information, future events or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201210006235/en/

Bob Brown

[email protected]

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Professional Services Finance

MEDIA:

December 10, 2020 9:53 pm

ROSEN, TRUSTED AND LEADING INVESTOR COUNSEL, Commences Investigation of Securities Claims Against Penumbra, Inc. Seeking Recovery of Investor Losses; Encourages Investors with Losses Over $100K to Seek Counsel – PEN

PR Newswire

NEW YORK, Dec. 10, 2020 /PRNewswire/ — Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Penumbra, Inc. (NYSE: PEN) resulting from allegations that Penumbra may have issued materially misleading business information to the investing public.

On November 10, 2020, Quintessential Capital Management released research report on the Company entitled “Penumbra and its ‘Killer Catheter’: A tale of corporate greed and seemingly blatant disregard for patients’ lives[.]”

On December 8, 2020, Quintessential Capital Management released a follow-up research report entitled “Is Penumbra’s core scientific research authored by a fake person?: The incredible story of Penumbra’s Dr. Antik Bose[.]” The follow-up report alleged that some of the Company’s scientific research pieces appear to have been incorrectly attributed or even authored by a fake individual. On this news, Penumbra’s share price fell $19.95 per share, or almost 9%, to close at $204.07 per share on December 8, 2020.

Rosen Law Firm is preparing a securities lawsuit on behalf of Penumbra shareholders. If you purchased securities of Penumbra please visit the firm’s website at http://www.rosenlegal.com/cases-register-2003.html to join the securities action. You may also contact Phillip Kim of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm’s attorneys are ranked and recognized by numerous independent and respected sources. Rosen Law Firm has secured hundreds of millions of dollars for investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————-

Contact Information:

      Laurence Rosen, Esq.
      Phillip Kim, Esq.
      The Rosen Law Firm, P.A.
      275 Madison Avenue, 40^th Floor
      New York, NY 10016
      Tel: (212) 686-1060
      Toll Free: (866) 767-3653
      Fax: (212) 202-3827
      [email protected]
      [email protected]
      [email protected]
      www.rosenlegal.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/rosen-trusted-and-leading-investor-counsel-commences-investigation-of-securities-claims-against-penumbra-inc-seeking-recovery-of-investor-losses-encourages-investors-with-losses-over-100k-to-seek-counsel–pen-301190956.html

SOURCE Rosen Law Firm, P.A.

December 10, 2020 9:51 pm

ImmunityBio’s hAd5 T-Cell COVID-19 Vaccine Candidate Shows Complete Protection of Airways in Non-Human Primates

ImmunityBio’s hAd5 T-Cell COVID-19 Vaccine Candidate Shows Complete Protection of Airways in Non-Human Primates

BARDA-sponsored study shows second-generation hAd5 vaccine candidate in both subcutaneous and room temperature oral formulations inhibits SARS-CoV-2 virus replication to undetectable levels and clears infection within days in 100% of vaccinated non-human primates

The second-generation human adenovirus vector hAd5, which delivers both outer spike (S) and inner nucleocapsid (N) antigens, induced T cells and antibodies leading to reduction of SARS-CoV-2 viruses in both lungs and nasal passages within seven days
The hAd5-COVID-19 oral capsule vaccine candidate was effective at room temperature in non-human primates suggesting that it may not require cold chain logistics that can impede global distribution
The hAd5-COVID-19 oral vaccine candidate will enter Phase 1 human trials as a prime and a boost and, pending discussions with the FDA, will be explored to provide a boost to subcutaneous vaccinations
Twenty participants have completed testing in the Phase 1 trial at Hoag Hospital Newport Beach, Calif., which evaluated both low and high doses of subcutaneous hAd5, with zero grade 3/4 adverse events reported. The Phase 2 trial is now actively recruiting.

CULVER CITY, Calif.–(BUSINESS WIRE)–
ImmunityBio, a privately-held immunotherapy company, today announced its COVID-19 vaccine candidate protected nasal and lung airways of non-human primates against coronavirus (SARS-CoV-2) in a challenge study. The study, sponsored by the Biomedical Advanced Research & Development Authority (BARDA), provides further evidence supporting the company’s use of a second-generation adenoviral vector that induces the immune system to both activate T cells and generate antibodies against multiple viral targets—blocking virus replication and clearing existing infection.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201210006234/en/

(Graphic: Business Wire)

In the study, immunization with the hAd5-COVID-19 vaccine inhibited SARS-CoV-2 virus replication in 100% (10 of 10) of Rhesus macaques, with a drop in viral replication starting on the first day of vaccine administration, and undetectable viral levels as early as three to five days post-challenge in most of the animals. The vaccine targeted both the inner nucleocapsid (N) and the outer spike (S) proteins of the virus to maximize the immune response. The goal of targeting both S and N was to both activate virus-specific T cells and generate anti-SARS-CoV-2-neutralizing antibodies. The study showed this broad immune response led to the complete clearance of the virus in a matter of days after infection of previously-vaccinated primates. This blocking of viral replication was observed in both the lung and nasal passages. By protecting the nasal passages (the primary point of entry for the virus), the vaccine has the potential to reduce reinfection. Clearing replicating viruses from nasal passages is critical for reducing transmission of the virus from immunized recipients to others.

The hAd5-COVID-19 candidate is designed to address a potential problem that may emerge when first-generation adenoviral platforms are used as vaccine vectors: vaccine inactivation due to pre-existing immunity to the vector itself. This risk exists for many vaccine candidates being tested in Europe, China, Russia, and the United States. Many people who have been exposed to the “common cold” potentially develop adenovirus immunity: the immune system often attacks and disables these first-generation vaccines before they can activate the immune response to attack the SARS-CoV-2 virus. This can significantly limit the effectiveness of first-generation platforms. ImmunityBio has engineered the vector to overcome this problem and has shown that its second-generation adenovirus vector can safely and effectively deliver its cargo even in patients with pre-existing adenovirus immunity.¹

“These results provide compelling evidence of the need for vaccines to target both S and N proteins and to activate T cells to produce immune system memory to combat this virus,” said Patrick Soon-Shiong, MD, Chairman and CEO of ImmunityBio. “The adage that ‘B cells forget but T cells remember’ has never been more important, and leveraging the S plus N combination has resulted in a vaccine that is not only showing evidence of being effective but also one that has the potential to provide long-term T-cell memory. The exciting finding that the thermally-stable oral formulation triggers immune responses sufficient to inhibit virus replication to undetectable levels bodes well for the possibility that this oral formulation could serve as a universal heterologous booster. Our oral capsule could be a solution to the enormous challenges facing cold chain logistics and enable global distribution of the vaccine.”

The manuscript detailing these preclinical data is available on a preprint server at https://biorxiv.org/cgi/content/short/2020.12.08.416297v1 and is concurrently undergoing scientific peer-review for potential publication.

In vivo Non-Human Primate (NHP) Challenge Study Design

This study was designed to test the safety, immunogenicity and protection from infection and disease provided by ImmunityBio’s hAd5-COVID-19 vaccine. The vaccine was administered in two separate regimens. In the first, primates received subcutaneous (SC) vaccination on Day 0, followed by an SC boost on Day 14 and an oral boost on Day 28. In the second, the SC prime was followed by two oral boosts on the same schedule. Placebo controls were used for comparison for both. Subcutaneous injection of hAd5 and oral administration of enteric-coated capsules in Rhesus macaques did not result in any treatment-related toxicities.

Study Highlights:

ImmunityBio’s hAd5-COVID-19 vaccine was determined to be well tolerated following both subcutaneous and oral capsule administration.
ImmunityBio’s hAd5 vaccine activated T cells to provide protection, and N was particularly effective in this role. This feature of the hAd5 vaccine distinguishes it from other vaccines.
ImmunityBio’s hAd5 vaccine generated robust neutralizing antibody activity that was present 14 days post-final vaccination. Additional safety and neutralizing data are currently being collected/analyzed.
Both vaccination regimens resulted in complete protection from subsequent viral ‘challenge’ as reflected by reductions in viral RNA levels that were below the level of detection by day seven post-challenge compared to controls.

hAd5-COVID-19 Oral Formulation

The hAd5-COVID-19 liquid drug substance was dried (lyophilized) and encapsulated to create the thermally-stable oral version of the vaccine. The capsules are enterically-coated to allow passage through the stomach to the small intestine, where the capsule dissolves to deliver the vaccine. Pending discussions with the FDA, the oral vaccine will enter Phase I trials as a prime and boost, and will be explored to provide a boost to subcutaneous vaccinations.

For more information about ImmunityBio’s COVID-19 vaccine trials, please contact [email protected].

About ImmunityBio and NantKwest Joint Collaboration Agreement

Under the terms of a definitive agreement announced on August 24, 2020, ImmunityBio, Inc. and its affiliate NantKwest, Inc. agreed to share equally the costs of development, manufacturing, marketing and commercialization of the products each is developing related to COVID-19, including the hAd5 vaccine candidate. Should a product be commercialized successfully, the companies have agreed to a 60-40 percent split of net profits, with the larger share going to the company that developed the product. The agreement also details the structure of shared governance of the joint collaboration.

^1.https://pubmed.ncbi.nlm.nih.gov/20361185/

^1.https://theoncologist.onlinelibrary.wiley.com/doi/full/10.1634/theoncologist.2019-0608

About ImmunityBio

ImmunityBio, Inc. is a late-clinical-stage immunotherapy company developing next-generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company’s immunotherapy platform activates both the innate (natural killer cell and macrophage) and adaptive (T-cell) immune systems to create long-term “immunological memory.” This novel approach is designed to eliminate the need for high-dose chemotherapy, improve upon the outcomes of current CAR T-cell therapies, and extend beyond checkpoint inhibitors.

ImmunityBio’s platform is based on the foundation of three separate modalities: antibody cytokine fusion proteins, synthetic immunomodulators, and second-generation human adenovirus (hAd5) vaccine technologies.

Anktiva™ (ImmunityBio’s lead cytokine infusion protein) is a novel interleukin-15 (IL-15) superagonist complex and has received Breakthrough Therapy and Fast Track Designations from the U.S. Food and Drug Administration (FDA) for BCG-unresponsive CIS non-muscle invasive bladder cancer (NMIBC). The company is also in Phase 2 or 3 trials for indications such as first- and second-line lung cancer, triple-negative breast cancer, metastatic pancreatic cancer, recurrent glioblastoma, and soft tissue sarcoma in combination with the company’s synthetic immune modulator (Aldoxorubicin).

ImmunityBio is also developing therapies, including vaccines, for the prevention and treatment of HIV, influenza, and the coronavirus SARS-CoV-2 with its second-generation human adenovirus (hAd5) vaccine technologies.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning or implying that ImmunityBio will be successful in improving the treatment of the novel coronavirus, the timing and results of the clinical development of hAd5-COVID-19 oral capsule vaccine, or whether ImmunityBio will be successful in gaining regulatory approval of, commercializing or distributing the vaccine. Risks and uncertainties related to these endeavors include, but are not limited to the successful completion of the currently contemplated Phase 1 trials and the currently enrolling Phase 2 trial and subsequent clinical development and FDA approval of the vaccine on the currently anticipated timeline, if at all, as well as manufacturing and distribution challenges. Risks and uncertainties related to this endeavor include, but are not limited to, the company’s beliefs regarding the success, cost, and timing of its development activities and clinical trials.

Forward-looking statements are based on management’s current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements speak only as of the date hereof, and we disclaim any obligation to update these statements except as may be required by law.

About NantKwest

NantKwest (NASDAQ: NK) is an innovative, clinical-stage immunotherapy company focused on harnessing the power of the innate immune system to treat cancer and infectious diseases. NantKwest is the leading producer of clinical dose forms of off-the-shelf natural killer (NK) cell therapies. The activated NK cell platform is designed to destroy cancer and virally-infected cells. The safety of these optimized, activated NK cells—as well as their activity against a broad range of cancers—has been tested in phase I clinical trials in Canada and Europe, as well as in multiple phase I and II clinical trials in the United States. By leveraging an integrated and extensive genomics and transcriptomics discovery and development engine, together with a pipeline of multiple, clinical-stage, immuno-oncology programs, NantKwest’s goal is to transform medicine by bringing novel NK cell-based therapies to routine clinical care. NantKwest is a member of the NantWorks ecosystem of companies. For more information, please visit www.nantkwest.com

Forward-Looking Statements

These and other risks regarding NantKwest’s business are described in detail in its Securities and Exchange Commission filings, including in NantKwest’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2020. These forward-looking statements speak only as of the date hereof, and we disclaim any obligation to update these statements except as may be required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201210006234/en/

Jen Hodson

NANT

[email protected]

562-397-3639

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Health Infectious Diseases Clinical Trials Research Science Pharmaceutical Biotechnology

MEDIA:

Logo

Photo

(Graphic: Business Wire)

December 10, 2020 9:49 pm

China Renaissance Served as Joint Global Coordinator for Pop Mart’s Successful Hong Kong IPO

China Renaissance’s Huaxing Growth Capital Backed Pop Mart’s Fundraising in May

PR Newswire

HONG KONG, Dec. 10, 2020 /PRNewswire/ — China Renaissance (“China Renaissance”, stock code: 1911.HK) served as the joint global coordinator for the successful initial public offering (“IPO”) of Pop Mart International Group Limited (“Pop Mart” or the “Company”, stock code: 9992.HK) on the Hong Kong Stock Exchange. Pop Mart raised approximately HK$6.01 billion with a total of 156 million shares (including the overallotment option) priced at HK$38.5 per share.

Pop Mart, China’s largest and fastest-growing pop toy company[1], intends to use the net proceeds raised to expand the Company’s consumer access channels and overseas markets, fund its potential investments in, acquisitions of and strategic alliance with companies along the industry value chain, invest in technology to strengthen its marketing and fan engagement efforts, and enhance the digitalization of its business while further expanding its intellectual property (“IP”) pool. With Intellectual Property (“IP”) operation as its core business, Pop Mart has established an integrated platform covering the entire industry chain of pop toys, including artists development, IP operation, consumer access and pop toy culture promotion, and is committed to “lighting up the passion of fans and bringing them joy”. As of June 30, 2020, Pop Mart managed a pool of 93 IPs and recorded 3.6 million registered members.

China Renaissance has developed a long-term partnership with Pop Mart by supporting the Company through various growth stages. Huaxing Growth Capital, the flagship investment arm of China Renaissance, backed Pop Mart’s fundraising in May 2020. Acting as Pop Mart’s Joint Global Coordinator on Pop Mart’s IPO, China Renaissance contributed to the Company’s successful listing by securing a number of quality investors.

Fan Bao, Chairman and Chief Executive Officer of China Renaissance and Founding Partner of Huaxing Growth Capital said: “We congratulate Pop Mart on its milestone offering. As a trailblazer of pop toy culture in China, Pop Mart has been leading the revolution of China’s pop toy culture, growing the industry from a niche market to the mainstream pop culture. Pop Mart is at the forefront of companies seeking to capitalize on the historic changes to the consumer market’s preferences, which are driven by the younger generation’s shift in consumption patterns. As an investor and a long-term partner, we believe that Pop Mart’s highest achievement lies ahead of it, and we look forward to working more closely with them going forward.”

The consumer internet sector has been a focus of China Renaissance’s investment banking team that advised on a variety of transactions in the sector, including strategic investments, convertible bonds issuances, private placements, M&A deals for industry leaders, such as JD.com, Pinduoduo, Gome, MissFresh, Club Factory, Meiri Yitao and Helijia.

In 2020, China Renaissance acted as the key advisor for 17 overseas IPOs and follow-on offering transactions of Chinese New Economy companies, with a total underwriting value of over US$23.6 billion. Transactions include the Hong Kong IPO of JD Health, the Hong Kong secondary listing of JD. Com, the U.S. IPO and follow-on offering of KE Holdings, the Hong Kong secondary listing of ZTO Express, the U.S. IPO of Lufax, and the U.S. IPO of Yatsen Global.

[1] According to the Frost & Sullivan Report based on Pop Mart’s 2019 retail value with an 8.5% market share and 2017 to 2019 revenue growth, respectively.

View original content:http://www.prnewswire.com/news-releases/china-renaissance-served-as-joint-global-coordinator-for-pop-marts-successful-hong-kong-ipo-301190957.html

SOURCE China Renaissance Holdings Limited

December 10, 2020 9:46 pm

Vivos Therapeutics Announces Pricing of $21M Initial Public Offering

HIGHLANDS RANCH, Colo., Dec. 10, 2020 (GLOBE NEWSWIRE) — Vivos
Therapeutics, Inc. (“
Vivos
”), a medical technology company that offers novel and proprietary alternatives for treating mild-to-moderate obstructive sleep apnea, today announced the pricing of its initial public offering of 3,500,000 shares of its common stock at a public offering price of $6.00 per share. The shares of common stock are expected to begin trading on the Nasdaq Capital Market under the ticker symbol “VVOS” on Friday, December 11, 2020.

The aggregate gross proceeds to Vivos from the public offering are expected to be $21 million prior to deducting underwriting discounts, commissions and other estimated offering expenses. Vivos has granted the underwriters a 45-day option to purchase up to an additional 525,000 shares of common stock to cover over-allotments, if any.

Roth Capital Partners is acting as lead book-running manager and representative of the underwriters for the offering. Craig-Hallum Capital Group and National Securities Corporation, a wholly owned subsidiary of National Holdings Corporation (NasdaqCM:NHLD) are acting as co-managers of the offering.

The Securities and Exchange Commission declared effective a registration statement on Form S-1 relating to these securities on December 10, 2020. A final prospectus relating to this offering will be filed with the Securities and Exchange Commission. The offering is being made only by means of a prospectus. Copies of the prospectus relating to the offering may be obtained, when available, by emailing Roth Capital Partners, 888 San Clemente, Newport Beach, CA 92660, Attn: Prospectus Department, telephone: 800-678-9147, or email at [email protected]; National Securities Corporation, 200 Vesey Street, 25th Floor, New York, NY 10281, telephone: (212) 417-3634 or by sending an e-mail to: [email protected]; or Craig-Hallum Capital Group LLC, 222 South Ninth Street, Suite 350, Minneapolis, MN 55402, Attn: Equity Capital Markets, telephone: 612-334-6300 or by email at [email protected]. Investors may also obtain these documents at no cost by visiting the Securities and Exchange Commission’s website at http://www.sec.gov.

Before you invest, you should read the prospectus and other documents the Company has filed or will file with the Securities and Exchange Commission for more complete information about the Company and the offering.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About
Vivos
Therapeutics, Inc.

Vivos Therapeutics Inc. is a medical technology company focused on the development and commercialization of a highly differentiated technology offering a clinically effective non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). We believe our products and technology represent a significant improvement in the treatment of mild-to-moderate OSA versus other treatments such as continuous positive airway pressure (or CPAP). For more information visit www.vivoslife.com.

Cautionary Note Concerning Forward-Looking Statements

This press release contains “forward-looking statements,” including with respect to the initial public offering. No assurance can be given that the offering discussed above will be completed on the terms described, or at all, or that the proceeds of the offering will be used as indicated. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company’s registration statement for the initial public offering filed with the SEC. Copies are available on the SEC’s website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Investor Relations Contacts:
Edward Loew
SVP Capital Markets
(602) 903-0095
[email protected]

Media Contacts:
Caitlin Kasunich / Jenny Robles
KCSA Strategic Communications
(212) 896-1241 / (917) 420-1444
[email protected] / [email protected]

December 10, 2020 9:19 pm

ROSEN, A LONGSTANDING AND TRUSTED FIRM, Reminds Berry Corporation Investors of Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm – BRY

PR Newswire

NEW YORK, Dec. 10, 2020 /PRNewswire/ — Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Berry Corporation (NASDAQ: BRY): (a) pursuant and/or traceable to the Company’s initial public offering conducted on or about July 26, 2018 (the “IPO” or “Offering”); and/or (b) between July 26, 2018 and November 3, 2020, both dates inclusive (the “Class Period”), of the important January 21, 2021 lead plaintiff deadline in securities class action. The lawsuit seeks to recover damages for Berry investors under the federal securities laws.

To join the Berry class action, go to http://www.rosenlegal.com/cases-register-1991.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

The complaint alleges that the Offering Documents, and, during the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Berry had materially overstated its operational efficiency and stability; (2) Berry’s operational inefficiency and instability would foreseeably necessitate operational improvements that would disrupt the Company’s productivity and increase costs; (3) the foregoing would foreseeably negatively impact the Company’s revenues; and (4) as a result, the Offering Documents and the Company’s public statements were materially false and/or misleading and failed to state information required to be stated therein. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 21, 2021. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-register-1991.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR’S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Contact Information:

Laurence Rosen, Esq.

Phillip Kim, Esq.

The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
[email protected]
[email protected]
www.rosenlegal.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/rosen-a-longstanding-and-trusted-firm-reminds-berry-corporation-investors-of-important-deadline-in-securities-class-action-encourages-investors-with-losses-in-excess-of-100k-to-contact-the-firm–bry-301190948.html

SOURCE Rosen Law Firm, P.A.